Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured

Authors: Takeo Suzuki, Kiyoko Kawamura, Quanhai Li, Shinya Okamoto, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima, Naoto Yamaguchi, Masatoshi Tagawa

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Transduction of human mesenchymal stem cells (MSCs) with type 5 adenoviruses (Ad5) is limited in the efficacy because of the poor expression level of the coxsackie adenovirus receptor (CAR) molecules. We examined a possible improvement of Ad-mediated gene transfer in MSCs by substituting the fiber region of type 5 Ad with that of type 35 Ad.

Methods

Expression levels of CAR and CD46 molecules, which are the major receptors for type 5 and type 35 Ad, respectively, were assayed with flow cytometry. We constructed vectors expressing the green fluorescent protein gene with Ad5 or modified Ad5 bearing the type 35 fiber region (AdF35), and examined the infectivity to MSCs with flow cytometry. We investigated anti-tumor effects of MSCs transduced with interleukin (IL)-28A gene on human lung carcinoma cells with a colorimetric assay. Expression of IL-28A receptors was tested with the polymerase chain reaction. A promoter activity of transcriptional regulatory regions in MSCs was determined with a luciferase assay and a tumor growth-promoting ability of MSCs was tested with co-injection of human tumor cells in nude mice.

Results

MSCs expressed CD46 but scarcely CAR molecules, and subsequently were transduced with AdF35 but not with Ad5. Growth of MSCs transduced with the IL-28A gene remained the same as that of untransduced cells since MSCs were negative for the IL-28A receptors. The IL-28A-transduced MSCs however suppressed growth of lung carcinoma cells co-cultured, whereas MSCs transduced with AdF35 expressing the β-galactosidase gene did not. A regulatory region of the cyclooygenase-2 gene possessed transcriptional activities greater than other tumor promoters but less than the cytomegalovirus promoter, and MSCs themselves did not support tumor growth in vivo.

Conclusions

AdF35 is a suitable vector to transduce MSCs that are resistant to Ad5-mediated gene transfer. MSCs infected with AdF35 that activate an exogenous gene by the cytomegalovirus promoter can be a vehicle to deliver the gene product to targeted cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284: 143-147. 10.1126/science.284.5411.143.CrossRefPubMed Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284: 143-147. 10.1126/science.284.5411.143.CrossRefPubMed
2.
go back to reference Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O, Houkin K, Matsunaga T, Niitsu Y: Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci. 2005, 96: 149-156. 10.1111/j.1349-7006.2005.00032.x.CrossRefPubMed Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O, Houkin K, Matsunaga T, Niitsu Y: Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci. 2005, 96: 149-156. 10.1111/j.1349-7006.2005.00032.x.CrossRefPubMed
3.
go back to reference Barry FP, Murphy JM: Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004, 36: 568-584. 10.1016/j.biocel.2003.11.001.CrossRefPubMed Barry FP, Murphy JM: Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004, 36: 568-584. 10.1016/j.biocel.2003.11.001.CrossRefPubMed
4.
go back to reference Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004, 96: 1593-1603. 10.1093/jnci/djh299.CrossRefPubMed Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004, 96: 1593-1603. 10.1093/jnci/djh299.CrossRefPubMed
5.
go back to reference Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K, Shayakhmetov D, Li Z, Strauss R, Stone D, Lieber A: A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol. 2006, 80: 12109-12120. 10.1128/JVI.01370-06.CrossRefPubMedPubMedCentral Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K, Shayakhmetov D, Li Z, Strauss R, Stone D, Lieber A: A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol. 2006, 80: 12109-12120. 10.1128/JVI.01370-06.CrossRefPubMedPubMedCentral
6.
go back to reference Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A: Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. Virol. 2000, 74: 2567-2583. 10.1128/JVI.74.6.2567-2583.2000.CrossRef Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A: Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. Virol. 2000, 74: 2567-2583. 10.1128/JVI.74.6.2567-2583.2000.CrossRef
7.
go back to reference Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M, Ogawa T, Kaiho I, Tagawa M: Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res. 2007, 27: 2311-2316.PubMed Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M, Ogawa T, Kaiho I, Tagawa M: Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res. 2007, 27: 2311-2316.PubMed
8.
go back to reference Gaggar A, Shayakhmetov DM, Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003, 9: 1408-1412. 10.1038/nm952.CrossRefPubMed Gaggar A, Shayakhmetov DM, Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003, 9: 1408-1412. 10.1038/nm952.CrossRefPubMed
9.
go back to reference Li Q, Kawamura K, Tada Y, Shimada H, Hiroshima K, Tagawa M: Novel type III interferons produce anti-tumor effects through multiple functions. Front Biosci (Landmark Ed). 2013, 18: 909-918. 10.2741/4152.CrossRef Li Q, Kawamura K, Tada Y, Shimada H, Hiroshima K, Tagawa M: Novel type III interferons produce anti-tumor effects through multiple functions. Front Biosci (Landmark Ed). 2013, 18: 909-918. 10.2741/4152.CrossRef
10.
11.
go back to reference Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T, Nakayama K, Numasaki M: Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci. 2011, 102: 1977-1990. 10.1111/j.1349-7006.2011.02079.x.CrossRefPubMed Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T, Nakayama K, Numasaki M: Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci. 2011, 102: 1977-1990. 10.1111/j.1349-7006.2011.02079.x.CrossRefPubMed
12.
go back to reference Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, Shimada H, Tagawa M: Interferon-λ induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer. 2010, 46: 180-190. 10.1016/j.ejca.2009.10.002.CrossRefPubMed Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, Shimada H, Tagawa M: Interferon-λ induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer. 2010, 46: 180-190. 10.1016/j.ejca.2009.10.002.CrossRefPubMed
13.
go back to reference Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV: Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma. Cancer Res. 2006, 66: 4468-4477. 10.1158/0008-5472.CAN-05-3653.CrossRefPubMed Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV: Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma. Cancer Res. 2006, 66: 4468-4477. 10.1158/0008-5472.CAN-05-3653.CrossRefPubMed
14.
go back to reference Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T: Antitumor activity of IFN-λ in murine tumor models. J Immunol. 2006, 176: 7686-7694. 10.4049/jimmunol.176.12.7686.CrossRefPubMed Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T: Antitumor activity of IFN-λ in murine tumor models. J Immunol. 2006, 176: 7686-7694. 10.4049/jimmunol.176.12.7686.CrossRefPubMed
15.
go back to reference Numasaki M, Tagawa M, Hidaka M, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M: IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol. 2007, 178: 5086-5098. 10.4049/jimmunol.178.8.5086.CrossRefPubMed Numasaki M, Tagawa M, Hidaka M, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M: IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol. 2007, 178: 5086-5098. 10.4049/jimmunol.178.8.5086.CrossRefPubMed
16.
go back to reference Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV: Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother. 2010, 59: 1059-1071. 10.1007/s00262-010-0831-3.CrossRefPubMedPubMedCentral Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV: Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother. 2010, 59: 1059-1071. 10.1007/s00262-010-0831-3.CrossRefPubMedPubMedCentral
17.
go back to reference Lasfar A, Cohen-Solal KA: Emergence of IFN-lambda as a potential antitumor agent. Targets in Gene Therapy. Edited by: You YP. 2011, Croatia: InTech, 15 Lasfar A, Cohen-Solal KA: Emergence of IFN-lambda as a potential antitumor agent. Targets in Gene Therapy. Edited by: You YP. 2011, Croatia: InTech, 15
18.
go back to reference Fushimi K, Iijima M, Gao C, Kondo T, Tsuji T, Hashimoto T, Mihara K, Namba M: Transformation of normal human fibroblasts into immortalized cells with the mutant p53 gene and X-rays. Int J Cancer. 1997, 70: 135-140. 10.1002/(SICI)1097-0215(19970106)70:1<135::AID-IJC20>3.0.CO;2-J.CrossRefPubMed Fushimi K, Iijima M, Gao C, Kondo T, Tsuji T, Hashimoto T, Mihara K, Namba M: Transformation of normal human fibroblasts into immortalized cells with the mutant p53 gene and X-rays. Int J Cancer. 1997, 70: 135-140. 10.1002/(SICI)1097-0215(19970106)70:1<135::AID-IJC20>3.0.CO;2-J.CrossRefPubMed
19.
go back to reference Compton T: An immortalized human fibroblast cell line is permissive for human cytomegalovirus infection. J Virol. 1993, 67: 3644-3648.PubMedPubMedCentral Compton T: An immortalized human fibroblast cell line is permissive for human cytomegalovirus infection. J Virol. 1993, 67: 3644-3648.PubMedPubMedCentral
20.
go back to reference Miyauchi M, Yoshida Y, Tada Y, Narita M, Maeda T, Bahar R, Kadomatsu K, Muramatsu T, Matsubara S, Nakagawara A, Sakiyama S, Tagawa M: Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells. Int J Cancer. 2001, 91: 723-727. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1112>3.0.CO;2-X.CrossRefPubMed Miyauchi M, Yoshida Y, Tada Y, Narita M, Maeda T, Bahar R, Kadomatsu K, Muramatsu T, Matsubara S, Nakagawara A, Sakiyama S, Tagawa M: Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells. Int J Cancer. 2001, 91: 723-727. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1112>3.0.CO;2-X.CrossRefPubMed
21.
go back to reference Kawamura K, Yu L, Tomizawa M, Shimozato O, Ma G, Li Q, Sato A, Yang Y, Suzuki T, Abdel-Aziz NM, Tagawa M: Transcriptional regulatory regions of the survivin gene activate an exogenous suicide gene in human tumors and enhance the sensitivity to a prodrug. Anticancer Res. 2007, 27: 89-93.PubMed Kawamura K, Yu L, Tomizawa M, Shimozato O, Ma G, Li Q, Sato A, Yang Y, Suzuki T, Abdel-Aziz NM, Tagawa M: Transcriptional regulatory regions of the survivin gene activate an exogenous suicide gene in human tumors and enhance the sensitivity to a prodrug. Anticancer Res. 2007, 27: 89-93.PubMed
22.
go back to reference Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT: Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther. 2001, 3: 385-394. 10.1006/mthe.2001.0275.CrossRefPubMed Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT: Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther. 2001, 3: 385-394. 10.1006/mthe.2001.0275.CrossRefPubMed
23.
24.
go back to reference Murakami S, Sakurai F, Kawabata K, Okada N, Fujita T, Yamamoto A, Hayakawa T, Mizuguchi H: Interaction of penton base Arg-Gly-Asp motifs with integrins is crucial for adenovirus serotype 35 vector transduction in human hematopoietic cells. Gene Ther. 2007, 14: 1525-1533. 10.1038/sj.gt.3303019.CrossRefPubMed Murakami S, Sakurai F, Kawabata K, Okada N, Fujita T, Yamamoto A, Hayakawa T, Mizuguchi H: Interaction of penton base Arg-Gly-Asp motifs with integrins is crucial for adenovirus serotype 35 vector transduction in human hematopoietic cells. Gene Ther. 2007, 14: 1525-1533. 10.1038/sj.gt.3303019.CrossRefPubMed
25.
go back to reference Knaän-Shanzer S, van de Watering MJ, van der Velde I, Gonçalves MA, Valerio D, de Vries AA: Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells. 2005, 23: 1598-1607. 10.1634/stemcells.2005-0016.CrossRefPubMed Knaän-Shanzer S, van de Watering MJ, van der Velde I, Gonçalves MA, Valerio D, de Vries AA: Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells. 2005, 23: 1598-1607. 10.1634/stemcells.2005-0016.CrossRefPubMed
26.
go back to reference Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC: The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011, 18: 488-495. 10.1038/gt.2010.170.CrossRefPubMedPubMedCentral Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC: The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011, 18: 488-495. 10.1038/gt.2010.170.CrossRefPubMedPubMedCentral
27.
go back to reference Wang GX, Zhan YA, Hu HL, Wang Y, Fu B: Mesenchymal stem cells modified to express interferon-β inhibit the growth of prostate cancer in a mouse model. J Int Med Res. 2012, 40: 317-327. 10.1177/147323001204000132.CrossRefPubMed Wang GX, Zhan YA, Hu HL, Wang Y, Fu B: Mesenchymal stem cells modified to express interferon-β inhibit the growth of prostate cancer in a mouse model. J Int Med Res. 2012, 40: 317-327. 10.1177/147323001204000132.CrossRefPubMed
28.
go back to reference Hakkarainen T, Särkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A, Hemminki A: Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther. 2007, 18: 627-641. 10.1089/hum.2007.034.CrossRefPubMed Hakkarainen T, Särkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A, Hemminki A: Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther. 2007, 18: 627-641. 10.1089/hum.2007.034.CrossRefPubMed
29.
go back to reference Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF: Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009, 69: 8932-8940. 10.1158/0008-5472.CAN-08-3873.CrossRefPubMedPubMedCentral Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF: Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009, 69: 8932-8940. 10.1158/0008-5472.CAN-08-3873.CrossRefPubMedPubMedCentral
30.
go back to reference García-Castro J, Alemany R, Cascalló M, Martínez-Quintanilla J, Arriero Mdel M, Lassaletta A, Madero L, Ramírez M: Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther. 2010, 17: 476-483. 10.1038/cgt.2010.4.CrossRefPubMed García-Castro J, Alemany R, Cascalló M, Martínez-Quintanilla J, Arriero Mdel M, Lassaletta A, Madero L, Ramírez M: Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther. 2010, 17: 476-483. 10.1038/cgt.2010.4.CrossRefPubMed
31.
go back to reference Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A, Tagawa M: Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther. 2007, 15: 1121-1128.PubMed Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A, Tagawa M: Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther. 2007, 15: 1121-1128.PubMed
32.
go back to reference Yu L, Hamada K, Namba M, Kadomatsu K, Muramatsu T, Matsubara S, Tagawa M: Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells. Eur J Cancer. 2004, 40: 1787-1794. 10.1016/j.ejca.2004.04.014.CrossRefPubMed Yu L, Hamada K, Namba M, Kadomatsu K, Muramatsu T, Matsubara S, Tagawa M: Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells. Eur J Cancer. 2004, 40: 1787-1794. 10.1016/j.ejca.2004.04.014.CrossRefPubMed
33.
go back to reference Ono HA, Davydova JG, Adachi Y, Takayama K, Barker SD, Reynolds PN, Krasnykh VN, Kunisaki C, Shimada H, Curiel DT, Yamamoto M: Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer. J Gastroenterol. 2005, 40: 31-42. 10.1007/s00535-004-1490-y.CrossRefPubMed Ono HA, Davydova JG, Adachi Y, Takayama K, Barker SD, Reynolds PN, Krasnykh VN, Kunisaki C, Shimada H, Curiel DT, Yamamoto M: Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer. J Gastroenterol. 2005, 40: 31-42. 10.1007/s00535-004-1490-y.CrossRefPubMed
34.
go back to reference Zhu ZB, Chen Y, Makhija SK, Lu B, Wang M, Rivera AA, Yamamoto M, Wang S, Siegal GP, Curiel DT, McDonald JM: Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int J Oncol. 2006, 29: 1319-1329.PubMed Zhu ZB, Chen Y, Makhija SK, Lu B, Wang M, Rivera AA, Yamamoto M, Wang S, Siegal GP, Curiel DT, McDonald JM: Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int J Oncol. 2006, 29: 1319-1329.PubMed
35.
go back to reference Yu L, Ugai S, O-Wang J, Namba M, Kadomatsu K, Muramatsu T, Matsubara S, Sakiyama S, Tagawa M: Cell growth- and p53-dependent transcriptional activity of the midkine promoter confers suicide gene expression in tumor cells. Oncol Rep. 2003, 10: 1301-1305.PubMed Yu L, Ugai S, O-Wang J, Namba M, Kadomatsu K, Muramatsu T, Matsubara S, Sakiyama S, Tagawa M: Cell growth- and p53-dependent transcriptional activity of the midkine promoter confers suicide gene expression in tumor cells. Oncol Rep. 2003, 10: 1301-1305.PubMed
36.
go back to reference Burke SJ, Collier JJ: The gene encoding cyclooxygenase-2 is regulated by IL-1β and prostaglandins in 832/13 rat insulinoma cells. Cell Immunol. 2011, 271: 379-384. 10.1016/j.cellimm.2011.08.004.CrossRefPubMed Burke SJ, Collier JJ: The gene encoding cyclooxygenase-2 is regulated by IL-1β and prostaglandins in 832/13 rat insulinoma cells. Cell Immunol. 2011, 271: 379-384. 10.1016/j.cellimm.2011.08.004.CrossRefPubMed
37.
go back to reference Ulivi V, Giannoni P, Gentili C, Cancedda R, Descalzi F: p38/NF-kB-dependent expression of COX-2 during differentiation and inflammatory response of chondrocytes. J Cell Biochem. 2008, 104: 1393-1406. 10.1002/jcb.21717.CrossRefPubMed Ulivi V, Giannoni P, Gentili C, Cancedda R, Descalzi F: p38/NF-kB-dependent expression of COX-2 during differentiation and inflammatory response of chondrocytes. J Cell Biochem. 2008, 104: 1393-1406. 10.1002/jcb.21717.CrossRefPubMed
Metadata
Title
Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured
Authors
Takeo Suzuki
Kiyoko Kawamura
Quanhai Li
Shinya Okamoto
Yuji Tada
Koichiro Tatsumi
Hideaki Shimada
Kenzo Hiroshima
Naoto Yamaguchi
Masatoshi Tagawa
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-713

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine